trending Market Intelligence /marketintelligence/en/news-insights/trending/q1xPW5dvWuS_s10jeJgpDQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Biopharma firm Transcenta raises US$100M in financing round

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Biopharma firm Transcenta raises US$100M in financing round

Chinese biopharmaceutical firm Transcenta Holding Ltd. raised US$100 million in a series B+ financing round.

New investors CR-CP Life Sciences Fund, Fortune Venture Capital Co. Ltd., Epiphron Capital, CCT China Merchant Buyout Fund, and China Equity Group participated in the round alongside existing shareholders Lilly Asia Ventures, Temasek, Hillhouse Capital, Teng Yue Partners LP, Sequoia Capital China, and Arch Venture Partners LP.

Transcenta was formed in January 2019 following the merger between MabSpace Biosciences in Hong Kong and HJB, which has sites in China and the U.S.